NASDAQ:EVO Evotec (EVO) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free EVO Stock Alerts $5.02 -0.08 (-1.57%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$4.99▼$5.1150-Day Range$5.10▼$7.8752-Week Range$4.87▼$13.49Volume869,112 shsAverage Volume140,344 shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Evotec alerts: Email Address Evotec MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside119.1% Upside$11.00 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.23) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.48 out of 5 starsMedical Sector466th out of 913 stocksPharmaceutical Preparations Industry202nd out of 420 stocks 3.5 Analyst's Opinion Consensus RatingEvotec has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvotec has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Evotec has been sold short.Short Interest Ratio / Days to CoverEvotec has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evotec has recently decreased by 20.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvotec does not currently pay a dividend.Dividend GrowthEvotec does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVO. Previous Next 2.3 News and Social Media Coverage News SentimentEvotec has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Evotec this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for EVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Evotec to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evotec insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Evotec is held by insiders.Percentage Held by InstitutionsOnly 5.81% of the stock of Evotec is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evotec are expected to grow in the coming year, from ($0.23) to $0.08 per share.Price to Book Value per Share RatioEvotec has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Evotec Stock (NASDAQ:EVO)Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Read More EVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVO Stock News HeadlinesApril 27, 2024 | americanbankingnews.comEvotec (NASDAQ:EVO) Price Target Cut to $11.00 by Analysts at HC WainwrightApril 27, 2024 | americanbankingnews.comHC Wainwright Weighs in on Evotec SE's Q1 2024 Earnings (NASDAQ:EVO)April 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 26, 2024 | finance.yahoo.comEvotec SE (ETR:EVT) Yearly Results: Here's What Analysts Are Forecasting For This YearApril 26, 2024 | americanbankingnews.comEvotec (NASDAQ:EVO) Hits New 12-Month Low at $5.10April 25, 2024 | finance.yahoo.comEvotec Full Year 2023 Earnings: EPS Misses ExpectationsApril 24, 2024 | seekingalpha.comEvotec: Still A Speculative Buy After A Significant DeclineApril 24, 2024 | finance.yahoo.comLife Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual ForecastApril 27, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 24, 2024 | seekingalpha.comEvotec SE 2023 Q4 - Results - Earnings Call PresentationApril 24, 2024 | investorplace.comWhy Is Evotec (EVO) Stock Down 33% Today?April 24, 2024 | investorplace.comWhy Is Evotec (EVO) Stock Down 33% Today?April 24, 2024 | marketwatch.comEvotec Shares Tumble After Company Books Significantly Lower EarningsApril 24, 2024 | msn.comTesla Surges 12% with 2025 Affordable Vehicle Promise, Evotec Slumps 36% on Uncertain Outlook, and Latest EarningsApril 24, 2024 | msn.comGerman drug maker Evotec sees increase in annual revenueApril 24, 2024 | markets.businessinsider.comEvotec Appoints Christian Wojczewski As CEOApril 24, 2024 | msn.comEvotec SE reports FY results; initiates FY24 outlookApril 23, 2024 | markets.businessinsider.comEQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive OfficerApril 22, 2024 | americanbankingnews.comReviewing InterCure (NASDAQ:INCR) and Evotec (NASDAQ:EVO)April 20, 2024 | americanbankingnews.comEvotec (NASDAQ:EVO) Shares Gap Down to $7.24April 19, 2024 | investing.comEvotec and Variant Bio partner to develop fibrosis treatmentsApril 18, 2024 | prnewswire.comEVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTSApril 17, 2024 | msn.comCompare with DAXsubsector All Industrial Machinery Index (4N67)April 15, 2024 | finance.yahoo.comEvoTec Power Set to Showcase Innovative Alternator Solutions at Middle East Energy 2024April 12, 2024 | msn.comEurope's STOXX 600 flat on rising Middle East tensions, energy stocks spikeApril 11, 2024 | ft.comDrugmakers race to find alternative suppliers as US cracks down on Chinese biotechApril 10, 2024 | msn.comGermany stocks mixed at close of trade; DAX up 0.11%See More Headlines Receive EVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EVO CUSIPN/A CIK1412558 Webwww.evotec.com Phone49-40-560-81-0Fax49-40-5608-1222Employees4,952Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+119.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.16 Quick Ratio2.09 Sales & Book Value Annual Sales$791.73 million Price / Sales2.25 Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book1.42Miscellaneous Outstanding Shares354,370,000Free Float350,827,000Market Cap$1.78 billion OptionableNot Optionable Beta1.36 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Mario Polywka DPHIL (Age 61)Ph.D., Interim CEO, Member of the Management Board & Member of the Supervisory Board Dr. Werner Lanthaler M.B.A. (Age 56)MPA, Ph.D., Member of Management Board Comp: $1.43MDr. Cord Dohrmann Ph.D. (Age 60)Chief Scientific Officer & Member of Management Board Comp: $870.88kDr. Craig Johnstone Ph.D. (Age 54)COO & Member of Management Board Comp: $771.22kDr. Matthias Evers Ph.D. (Age 51)Chief Business Officer & Member of Management Board Comp: $688.9kMs. Laetitia Rouxel (Age 50)CFO & Member of Management Board Ms. Anja BoslerPrincipal Accounting Officer and Senior Vice President of Group AccountingMr. Volker BraunSenior VP and Global Head of Investor Relations & ESGDr. Christian DargelEVP Global Head of Legal & ComplianceGabriele HansenSenior VP & Head of Global Corporate Communications & MarketingMore ExecutivesKey CompetitorsMorphoSysNASDAQ:MORACADIA PharmaceuticalsNASDAQ:ACADMoonLake ImmunotherapeuticsNASDAQ:MLTXSummit TherapeuticsNASDAQ:SMMTJanux TherapeuticsNASDAQ:JANXView All CompetitorsInstitutional OwnershipMubadala Investment Co PJSCBought 4,597,701 shares on 3/5/2024Ownership: 1.297%Optiver Holding B.V.Bought 69,936 shares on 2/13/2024Ownership: 0.023%Quadrant Capital Group LLCBought 2,130 shares on 2/8/2024Ownership: 0.001%Federated Hermes Inc.Sold 1,600 shares on 1/31/2024Ownership: 0.163%Zurcher Kantonalbank Zurich CantonalbankSold 28,102 shares on 1/30/2024Ownership: 0.049%View All Institutional Transactions EVO Stock Analysis - Frequently Asked Questions Should I buy or sell Evotec stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVO shares. View EVO analyst ratings or view top-rated stocks. What is Evotec's stock price target for 2024? 3 analysts have issued 12-month price targets for Evotec's shares. Their EVO share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 119.1% from the stock's current price. View analysts price targets for EVO or view top-rated stocks among Wall Street analysts. How have EVO shares performed in 2024? Evotec's stock was trading at $11.73 at the beginning of the year. Since then, EVO stock has decreased by 57.2% and is now trading at $5.02. View the best growth stocks for 2024 here. Are investors shorting Evotec? Evotec saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 59,200 shares, a decline of 20.4% from the March 31st total of 74,400 shares. Based on an average trading volume of 75,300 shares, the short-interest ratio is currently 0.8 days. Approximately 0.0% of the shares of the company are sold short. View Evotec's Short Interest. When did Evotec IPO? Evotec (EVO) raised $435 million in an initial public offering on Thursday, November 4th 2021. The company issued 20,000,000 shares at $21.75 per share. How do I buy shares of Evotec? Shares of EVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
